FY2024 EPS Estimates for MDxHealth Lifted by William Blair

MDxHealth SA (NASDAQ:MDXH) – William Blair increased their FY2024 earnings per share estimates for shares of MDxHealth in a note issued to investors on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the company will earn ($1.08) per share for the year, up from their prior estimate of ($1.11). The consensus estimate for MDxHealth’s current full-year earnings is ($1.16) per share. William Blair also issued estimates for MDxHealth’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.53) EPS.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, August 21st. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $22.16 million for the quarter, compared to analyst estimates of $20.66 million.

MDXH has been the subject of several other reports. Piper Sandler lowered their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Lake Street Capital initiated coverage on MDxHealth in a research report on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective for the company.

MDxHealth Stock Down 2.8 %

Shares of NASDAQ MDXH opened at $1.75 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The company has a 50-day simple moving average of $2.19 and a 200-day simple moving average of $2.57. MDxHealth has a 12 month low of $1.62 and a 12 month high of $4.64.

Institutional Investors Weigh In On MDxHealth

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXH. OneDigital Investment Advisors LLC increased its position in MDxHealth by 15.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares in the last quarter. MVM Partners LLC grew its stake in MDxHealth by 3.3% during the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after buying an additional 150,000 shares during the period. Finally, Perkins Capital Management Inc. increased its position in shares of MDxHealth by 70.7% in the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after acquiring an additional 309,500 shares in the last quarter.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.